Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Marbocil Capsules, an innovative antiviral drug for treating influenza in healthy adolescents and adults [1][2]. Drug Registration Details - Drug Name: Marbocil Capsules - English/Latin Name: Pixavir Marboxil Capsules - Dosage Form: Capsule - Specification: 20mg - Registration Classification: Class 1 Chemical Drug - License Holder: Health元药业集团股份有限公司 - Manufacturing Company: 凯莱英生命科学技术(天津)有限公司 - Approval Number: 国药准字H20250070 - Approval Conclusion: The drug meets the registration requirements and has been granted a registration certificate [1]. Drug Development and Clinical Data - Marbocil Capsules are indicated for the treatment of uncomplicated influenza A and B in healthy individuals aged 12 and above, excluding those at high risk for complications [2]. - The approval is based on a Phase III, multi-center, randomized, double-blind study demonstrating the drug's efficacy and safety compared to a placebo [2]. - The drug requires only a single dose for the entire treatment course, significantly improving patient compliance [3]. - In clinical trials, the median time to symptom relief for the treatment group was reduced by 27 hours compared to the placebo group (P<0.0001) [3]. - For patients with influenza B, the median time to symptom relief was shortened by 31 hours (P<0.05) [3]. - In adolescents, the median time to symptom relief was reduced by 61 hours compared to the placebo group (P<0.05) [3]. - The drug shows a lower risk of resistance, with a total incidence of amino acid substitutions related to sensitivity decline being 0% for H1N1, 1.2% for H3N2, and 0% for influenza B [3]. - The safety profile is favorable, with a low incidence of adverse reactions compared to the placebo group [3]. Market Situation - Influenza poses a global public health issue, with seasonal outbreaks causing significant health impacts [5]. - The estimated domestic sales of antiviral drugs for influenza are projected to reach approximately RMB 4.7 billion in 2024 [5]. R&D Investment - The cumulative direct investment in the research and development of Marbocil Capsules is approximately RMB 203.0361 million [4].

Core Viewpoint - The company is making significant progress in the field of anti-influenza products, with its core product, the innovative drug Marpaviroc capsules, nearing the final stages of review and set to be launched soon [1] Product Development - The Marpaviroc dry suspension for children has successfully entered Phase III clinical trials, indicating strong advancement in pediatric formulations [1] - The drug has notable advantages, including the ability to precisely block the replication of both influenza A and B viruses from the source, requiring only a single oral dose to complete the entire treatment course [1] - The pediatric formulation is highly adaptable and presents a low risk of resistance, with good safety profiles [1] Market Strategy - The company aims to accelerate the subsequent rollout of both products, striving to provide high-quality and convenient influenza treatment solutions for all age groups [1]

Core Viewpoint - The recent monitoring data from the Chinese Center for Disease Control and Prevention indicates a significant rise in influenza cases, with the percentage of influenza-like cases reaching 6.5%, signaling a rapid increase in flu activity across the country. This surge has led to a dramatic increase in sales of antiviral medications, particularly oseltamivir and baloxavir marboxil, with sales of oseltamivir increasing by 237% in one week and baloxavir marboxil rising by 180% [1][4][8]. Group 1: Market Dynamics - The sales of oseltamivir capsules in the domestic hospital market are projected to reach nearly 1.9 billion yuan in 2024, with Dongyang Sunshine Pharmaceutical holding a market share of 56.66%, dominating the domestic hospital market [4]. - Following the expiration of Roche's patent in 2016, numerous domestic generic versions of oseltamivir have emerged, with 138 related drug approvals currently available, indicating increased competition for Dongyang Sunshine Pharmaceutical [7]. - Baloxavir marboxil, developed by Roche, has seen its sales in the domestic market exceed 400 million yuan in 2023, with a projected sales figure of nearly 1.4 billion yuan in 2024, reflecting a year-on-year growth of 216.54% [8]. Group 2: Innovation and New Entrants - New domestic antiviral drugs are emerging, with Qingfeng Pharmaceutical's GP681, a first-class new drug for influenza, approved for the market in March 2025, providing a new treatment option for influenza patients aged 12 and older [13]. - The launch of innovative drugs such as Amlodipine tablets by Zhongsheng Pharmaceutical in May 2025 marks a significant breakthrough in the antiviral drug development field in China, potentially allowing the country to secure a position in the global influenza market [15]. - The inclusion of Jichuan Pharmaceutical's Jin Tong Bei and Ji Ke Shu in the first batch of the Jiangsu Province Innovation Drug and Device Product Directory highlights the recognition of their advanced technology and clinical value, enhancing their competitive edge in the antiviral market [21]. Group 3: Overall Market Trends - The current landscape of China's antiviral drug market is characterized by a combination of steady growth in traditional products and explosive growth in innovative products, with Dongyang Sunshine Pharmaceutical leading the market with oseltamivir, while Roche's baloxavir marboxil rapidly gains traction due to its unique advantages [22].

Core Insights - The flu medication market is undergoing a significant transformation, with Oseltamivir losing popularity and Marboxilavir rapidly gaining traction as a preferred treatment option [2][14]. Group 1: Market Dynamics - Oseltamivir, once the dominant flu treatment since its introduction in 1999, is experiencing a decline in market interest, with sales dropping significantly from over 6.5 billion yuan in 2019 to approximately 206.8 million yuan in 2020, a decrease of 65.1% [5][7]. - In contrast, Marboxilavir, which was approved in Japan in 2018 and in China in 2021, is witnessing a surge in demand, with sales reaching 510 million yuan in 2024 and capturing 10.8% of the market share [9][11]. Group 2: Competitive Landscape - The competition in the flu medication market is intensifying, with over 120 companies producing flu medications in China, including more than 70 competitors for Oseltamivir alone [8][16]. - New entrants like Marboxilavir are disrupting the market dynamics, leading to a potential dual dominance scenario alongside Oseltamivir, while other new drugs like Baloxavir and Mavrilavir are also emerging [16][17]. Group 3: Consumer Preferences - Marboxilavir's unique advantage of requiring only a single dose for treatment enhances patient compliance, making it particularly appealing for busy individuals and parents managing children's medication [11][12]. - Clinical studies indicate that Marboxilavir offers faster symptom relief compared to Oseltamivir, with an average symptom alleviation time of 53.7 hours versus longer durations for Oseltamivir [11][12]. Group 4: Future Outlook - The shift in market preference from Oseltamivir to Marboxilavir is expected to drive further research and development in the flu medication sector, fostering innovation and the introduction of more effective and safer treatments [18]. - Companies are encouraged to enhance their core competencies, optimize production processes, and leverage technologies like AI and big data to improve drug development and market strategies [17][18].

Overview - The demand for antiviral drugs in China is significantly influenced by the number of influenza cases, with the market size reaching 11 billion yuan in 2023, a year-on-year increase of 150% [1][7] - In 2024, the market size is expected to decrease to 8 billion yuan due to a reduction in influenza cases, with oseltamivir accounting for approximately 78% of the market [1][7] Industry Chain - The upstream of the antiviral drug industry includes suppliers of raw materials such as chemical APIs, traditional Chinese medicine materials, and packaging materials, while the midstream consists of antiviral drug manufacturers, and the downstream includes medical institutions, pharmacies, and e-commerce platforms [4] Development Background - The large population base in China leads to a high susceptibility to influenza, with an estimated 8.59 million cases and 19 deaths in 2024, driving demand for antiviral drugs, especially among the elderly [6][7] - Increased health awareness among the public has led to a greater willingness to purchase antiviral medications during flu season [6] Current Market Situation - The antiviral drug market in China is heavily influenced by influenza case numbers, with a significant expansion in 2023 due to a broader and longer-lasting influenza outbreak compared to pre-COVID-19 times [1][7] - The market is projected to contract in 2024 as influenza cases decline [1][7] Competitive Landscape - The antiviral drug market is currently dominated by neuraminidase inhibitors, with oseltamivir being the primary product, facing increasing competition from generic versions after its patent expired [8][9] - As of August 2025, there are 118 approved oseltamivir products from 69 companies, indicating a highly competitive environment [9] Key Companies - **East Sunshine Pharmaceutical**: Holds a 64.8% market share in the oseltamivir market and a 50.5% share in the overall antiviral market, with a revenue of 4.019 billion yuan in 2024 [10] - **Shijiazhuang Pharmaceutical Group**: Focuses on innovative drugs and reported a revenue of 29.01 billion yuan in 2024, with a gross profit margin of 69.97% [11] Development Trends - The rapid mutation of influenza viruses is driving research towards more effective antiviral drugs with lower resistance rates, particularly RNA polymerase inhibitors [11] - The emergence of innovative domestic drugs is expected to enhance China's position in the global antiviral market, with potential for international expansion of products with independent intellectual property rights [11]

Core Viewpoint - The market for antiviral drugs, particularly oseltamivir, is undergoing significant changes due to price adjustments, increased competition from generics, and the emergence of new drugs, leading to a potential reshaping of the industry landscape [1][3][12]. Price Adjustments and Market Dynamics - Zhejiang Province's medical insurance bureau has announced price adjustments for oseltamivir capsules, affecting several manufacturers, including East Sunshine Pharmaceutical [1][4]. - Prior to the collective procurement, oseltamivir capsules were priced over 100 yuan, but the minimum winning price in the seventh national procurement was less than 1 yuan per capsule, representing a 92% reduction from the highest bid [1][5]. - The domestic flu drug market exceeded 10 billion yuan in 2023, with oseltamivir holding over 80% market share, but this is threatened by the rapid growth of Roche's baloxavir marboxil, which saw sales increase from 70 million yuan in 2022 to 630 million yuan in 2023 [2][5]. Competitive Landscape - East Sunshine Pharmaceutical's market share for oseltamivir has dropped to 54.8% as of 2024, facing competition from over 70 other pharmaceutical companies producing generic versions [2][6]. - The company’s sales from oseltamivir products accounted for 81.2%, 86.9%, and 64.2% of total revenue from 2022 to 2024, indicating a significant reliance on this product line [7]. - The expiration of key patents for oseltamivir will intensify competition, with the last synthesis process patent expiring in March 2024 [5][6]. New Drug Developments - The introduction of new antiviral drugs, such as baloxavir marboxil and PB2-targeting drug, has the potential to disrupt the existing market, particularly with baloxavir's pediatric formulation targeting children aged 5 to 12 [8][10]. - The increasing resistance rates of flu viruses to existing treatments, including oseltamivir, highlight the urgent need for new drug development [10][11]. - The approval of multiple new antiviral drugs in China and the U.S. indicates a growing focus on innovative treatments to address flu virus mutations and resistance issues [9][10]. Future Outlook - The ongoing shifts in the antiviral drug market, driven by pricing pressures, patent expirations, and the introduction of new therapies, suggest that companies like East Sunshine Pharmaceutical may need to diversify their product offerings to sustain growth [7][12]. - The competitive landscape is expected to evolve rapidly, with both domestic and international players vying for market share in the antiviral segment [12].

Core Viewpoint - The approval of ZHONGSHENG Pharmaceutical's Angladiwe Tablets by the National Medical Products Administration marks a significant advancement in the treatment of influenza, being the first RNA polymerase PB2 protein inhibitor globally [1] Company Summary - ZHONGSHENG Pharmaceutical (002317) announced the approval of Angladiwe Tablets on May 22, 2025, for the treatment of adult uncomplicated influenza A patients [1] - Angladiwe Tablets are the only antiviral drug in China that has undergone head-to-head Phase III clinical trials against Oseltamivir and received market approval [1] Clinical Trial Results - Phase III clinical trial results indicated that Angladiwe Tablets significantly outperformed the placebo group in seven primary endpoints related to the relief of influenza symptoms, achieving statistical significance [1] - The Angladiwe group demonstrated a nearly 10% reduction in median time to alleviation of total symptoms (TTAS) and fever relief compared to the Oseltamivir group [1]